他汀类药物对慢性阻塞性肺疾病稳定期患者炎性因子影响作用研究

Effect of statins on inflammatory factors of patients with stable COPD

目的探讨他汀类药物在慢性阻塞性肺疾病(慢阻肺)稳定期应用的临床意义。方法选取100例门诊的慢阻肺稳定期患者,要求肺功能符合:30%<FEV1≤50%。随机分为实验组(使用瑞舒伐他汀)50例,对照组50例,均给予指南规定的吸入糖皮质激素抗炎、解痉平喘、化痰等,对于实验组,给予口服瑞舒伐他汀5 mg,每晚一次,持续4周。检测患者治疗前、后血浆中:白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白介素-8(IL-8)、C-反应蛋白(C-RP)水平的变化。结果对照组患者治疗前后血浆内IL-6、TNF-α、IL-8、C-RP改善程度无统计学意义(P>0.05),实验组中治疗前后IL-6、TNF-α、IL-8改善程度,具有统计学意义(P<0.05),C-RP改善程度无统计学意义(P>0.05);组间对比实验组较对照组中IL-6、TNF-α、IL-8改善程度有统计学意义(P<0.05),C-RP改变无统计学意义(P>0.05)。结论他汀类药物在治疗慢阻肺稳定期患者中,能减低患者体内的IL-6、TNF-α、IL-8水平,从而缓解患者体内炎症反应和免疫反应,减轻肺组织的炎症损伤。

Objective To investigate the clinical significance of statins in the treament of patients with stable chronic obstructive pulmonary disease （COPD）. Methods 100 stable COPD patients were randomly divided into two groups, the experimental group （rosuvastatin） and the control group, 50 cases in each group. The experimental group was orally given 5mh of rosuvastatin for 4 weeks. The plasma levels of interleukin-6 （IL-6） , tumor necrosis factor-α （TNF-α） , intedeukin-8 （IL-8） and C-reactive protein （CRP） were measured before and after the treat- ment. Results There was no significant difference in plasma IL-6, TNF-α, IL-8 and C-RP in the control group before and after the treatment （ P 〉 0. 05 ）. The improvement of IL-6, TNF-α and IL-8 was pronounced in the experimental group after the treatment （ P 〈 0. 05 ）, but the level of CRP showed no significant difference （ P 〉 0. 05 ）. Conclusion Statins can reduce the levels of IL-6, TNF-α and IL-8 in the treatment of patients with stable COPD, and thus relieve the body of inflammation and immune responses and reduce inflammation of lung tissue damage.